Valneva SE (VALN)
8.69
-0.19
(-2.14%)
USD |
NASDAQ |
May 20, 10:37
Valneva Debt to Equity Ratio: 0.9589 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.9589 |
| December 31, 2023 | 1.379 |
| September 30, 2023 | 0.8942 |
| June 30, 2023 | 0.5003 |
| March 31, 2023 | 0.4756 |
| December 31, 2022 | 0.4495 |
| September 30, 2022 | 0.6416 |
| June 30, 2022 | 0.8429 |
| March 31, 2022 | |
| December 31, 2021 | 0.339 |
| September 30, 2021 | |
| June 30, 2021 | 0.7069 |
| March 31, 2021 | 1.047 |
| December 31, 2020 | 0.6892 |
| September 30, 2020 | 0.7051 |
| June 30, 2020 | 0.4966 |
| March 31, 2020 | 0.3199 |
| December 31, 2019 | 0.1947 |
| September 30, 2019 | 0.1965 |
| June 30, 2019 | 0.1123 |
| March 31, 2019 | 0.1174 |
| December 31, 2018 | 0.2161 |
| September 30, 2018 | 0.6726 |
| Date | Value |
|---|---|
| June 30, 2018 | 0.6742 |
| March 31, 2018 | 0.7022 |
| December 31, 2017 | 0.4745 |
| September 30, 2017 | 0.7267 |
| June 30, 2017 | 0.7548 |
| March 31, 2017 | 0.7575 |
| December 31, 2016 | 0.541 |
| September 30, 2016 | 0.8219 |
| June 30, 2016 | 0.7717 |
| March 31, 2016 | 0.5897 |
| December 31, 2015 | 0.506 |
| September 30, 2015 | 0.606 |
| June 30, 2015 | 0.5912 |
| March 31, 2015 | 0.5734 |
| December 31, 2014 | 0.3463 |
| September 30, 2014 | 0.5226 |
| June 30, 2014 | 0.501 |
| March 31, 2014 | 0.5198 |
| December 31, 2013 | 0.2793 |
| September 30, 2013 | 0.3418 |
| June 30, 2013 | 0.655 |
| March 31, 2013 | |
| December 31, 2012 | 0.2563 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.1123
Minimum
Jun 2019
1.379
Maximum
Dec 2023
0.6083
Average
0.5709
Median
Debt to Equity Ratio Benchmarks
| DBV Technologies SA | -- |
| Cellectis SA | 0.3968 |
| PHAXIAM Therapeutics SA (DELISTED) | -- |
| Genfit SA | 0.9462 |
| Innate Pharma SA | 0.7525 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 543.00M |
| Total Liabilities (Quarterly) | 338.66M |
| Shareholders Equity (Quarterly) | 204.35M |
| Current Ratio | 2.638 |
| Net Debt Paydown Yield | -3.27% |